AIM ImmunoTech Inc.

AIM UA

AIM UAAIM ImmunoTech Inc.

NYSE MKT LLC

0.43

USD

-0.02

(-5.32%)

-0.64EPS Dil.

-0.67P/E

21.26MMarket Cap

AIM ImmunoTech Inc.

AIM:UA

(NYSE MKT LLC)

Recent

price

0.43

P/E

ratio

-0.67

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 06/18

Stock

S&P500

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.87	0.54	0.53	0.63	0.8	0.47	0.55	0.3	0.19	0.67	0.37	0.04	0.01	- -	- -	- -	- -	Revenue per Share
-86.05	-34.69	-51.72	-35.21	-65	-51.18	-48.88	-34.07	-15.12	-12.67	-9.79	-2.58	-0.45	-0.4	-0.4	-0.6	-0.64	Basic EPS, GAAP
-67.42	-47.69	-50.99	-47.39	-71.54	-56.91	-41.25	-37.01	-15.79	-12.29	-10.72	-2.59	-0.34	-0.31	-0.34	-0.44	-0.46	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
-1,342.38	-814.57	-866.89	-881.73	-774.37	-815.52	-719.08	-624.69	-546.32	-413.29	-287.52	-31.54	-8.11	-7.52	-7.91	-8.34	-8.26	Book Value per Share
71.94	230.54	179.89	144.37	138.62	88.46	62.55	41.6	26.59	10.5	3.85	1.11	1.4	1.13	0.75	0.15	0.04	Tangible Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	1	1	4	32	47	48	49	49	Basic Weighted Avg Shares
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Sales/Revenue/Turnover
-4,834.34	-11,949.55	-12,138.52	-8,878.88	-9,549.3	-11,444.67	-9,694.92	-12,518.8	-15,004.35	-2,612.36	-3,132.43	-8,887.86	-9,212.88	-12,636.3	-14,129.79	-15,800	-17,282.9	Operating Margin (%)
1	1	1	1	1	1	1	1	1	1	1	1	1	1	- -	- -	- -	Depreciation Expense
-12	-7	-13	-9	-17	-16	-17	-15	-8	-8	-10	-9	-14	-19	-19	-29	-31	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
-4,610.94	-6,468.47	-9,730.37	-5,599.38	-8,147.42	-10,816.67	-8,857.87	-11,451.13	-8,154.35	-1,889.93	-2,677.66	-6,717.14	-8,834.36	-14,168.15	-13,790.78	-14,337.62	-16,123.32	Profit Margin (%)
6	56	34	27	32	16	12	8	5	1	-1	9	39	50	35	6	1	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	2	2	6	2	- -	1	- -	1	LT Debt
12	59	46	38	45	29	25	20	15	9	5	13	61	57	38	10	5	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	31.21%	-2.98%	43.26%
Net Income, GAAP	10.54%	26.45%	48.94%
Free Cash Flow	5.7%	15.81%	29.84%
Total Cash Common Dividend	- -	- -	- -
Total Equity	26.13%	80.56%	-73.4%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Company News

benzinga
15 days ago
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
benzinga
a month ago
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
tipranks.com
a month ago
Buy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline Progress
GuruFocus.com
a month ago
AIM ImmunoTech Inc (AIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Advances Amid Financial Stability
GuruFocus.com
a month ago
Q1 2024 AIM ImmunoTech Inc Earnings Call Transcript
seekingalpha
a month ago
AIM ImmunoTech GAAP EPS of -$0.12
benzinga
a month ago
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
benzinga
a month ago
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
tipranks.com
2 months ago
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)

	Sep'23	Dec'23	Mar'24
Total Current Assets	23	15	11
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	22	13	11
Inventories	- -	- -	- -
Total Current Liabilities	5	9	10
Payables & Accruals	4	8	8
ST Debt	- -	- -	2
Deferred Revenue	- -	- -	- -

	Sep'23	Dec'23	Mar'24
ST Debt	- -	- -	2
LT Borrowings	- -	- -	1
LT Finance Leases	1	- -	1
Preferred Equity and Hybrid Capital	1	1	1
Shares Outstanding	49	49	50
Market Capitalization	21	23	24

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
1.87	0.54	0.53	0.63	0.8	0.47	0.55	0.3	0.19	0.67	0.37	0.04	0.01	- -	- -	- -	- -	Revenue per Share
-86.05	-34.69	-51.72	-35.21	-65	-51.18	-48.88	-34.07	-15.12	-12.67	-9.79	-2.58	-0.45	-0.4	-0.4	-0.6	-0.64	Basic EPS, GAAP
-67.42	-47.69	-50.99	-47.39	-71.54	-56.91	-41.25	-37.01	-15.79	-12.29	-10.72	-2.59	-0.34	-0.31	-0.34	-0.44	-0.46	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
-1,342.38	-814.57	-866.89	-881.73	-774.37	-815.52	-719.08	-624.69	-546.32	-413.29	-287.52	-31.54	-8.11	-7.52	-7.91	-8.34	-8.26	Book Value per Share
71.94	230.54	179.89	144.37	138.62	88.46	62.55	41.6	26.59	10.5	3.85	1.11	1.4	1.13	0.75	0.15	0.04	Tangible Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	1	1	4	32	47	48	49	49	Basic Weighted Avg Shares
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Sales/Revenue/Turnover
-4,834.34	-11,949.55	-12,138.52	-8,878.88	-9,549.3	-11,444.67	-9,694.92	-12,518.8	-15,004.35	-2,612.36	-3,132.43	-8,887.86	-9,212.88	-12,636.3	-14,129.79	-15,800	-17,282.9	Operating Margin (%)
1	1	1	1	1	1	1	1	1	1	1	1	1	1	- -	- -	- -	Depreciation Expense
-12	-7	-13	-9	-17	-16	-17	-15	-8	-8	-10	-9	-14	-19	-19	-29	-31	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
-4,610.94	-6,468.47	-9,730.37	-5,599.38	-8,147.42	-10,816.67	-8,857.87	-11,451.13	-8,154.35	-1,889.93	-2,677.66	-6,717.14	-8,834.36	-14,168.15	-13,790.78	-14,337.62	-16,123.32	Profit Margin (%)
6	56	34	27	32	16	12	8	5	1	-1	9	39	50	35	6	1	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	2	2	6	2	- -	1	- -	1	LT Debt
12	59	46	38	45	29	25	20	15	9	5	13	61	57	38	10	5	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2022	-0.08	-0.1	-0.13	-0.09	-0.4
2023	-0.08	-0.1	-0.16	-0.26	-0.6
2024	-0.12	- -	- -	- -	- -